with an MI hospitalization (defined by an inpatient claim with a code of 410.x0/410.x1 in any diagnosis position) between January 1, 2007, and December 31, 2012, whose initial statin fill within 30 days of hospital discharge was for a high-intensity dosage (eFigure 1 in the Supplement)...
High-intensity statins reduce CVD risk following AMI among patients with and without DM. We determined the proportion of Medicare beneficiaries 66 to 75years of age taking a low/moderate-intensity statin with (n=6718) and without (n=6414) DM who titrated to a high-intensity statin dosage (i...
However, of those on high-intensity statin, 25% remained on insufficient statin dosage. Conclusion Switch to high-intensity statins and use of ezetimibe and PCSK9i was low in chronic ASCVD patients. Even though statin intake was high in high-risk patients, target levels were still not reached...
Accordingly, we designed the ASTEROID trial (A Study to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound-Derived Coronary Atheroma Burden) to examine the effects of high-intensity statin therapy on IVUS-derived measures of coronary disease progression. Rosuvastatin is the most recently ...
However, of those on high-intensity statin, 25% remained on insufficient statin dosage. Conclusion: Switch to high-intensity statins and use of ezetimibe and PCSK9i was low in chronic ASCVD patients. Even though statin intake was high in high-risk patients, target levels were still not ...
et al. CYP3A4*1B and CYP3A5*3 SNPs significantly impact the response of Egyptian candidates to high-intensity statin therapy to atorvastatin. Eur J Med Res 29, 539 (2024). https://doi.org/10.1186/s40001-024-02109-7 Download citation Received10 June 2024 Accepted14 October 2024 Published...
The PROVE-IT study (Khush and Waters, 2004) suggested that statin dose may be more important than LDL-c levels, whereas the REVERSAL and ASTEROID trials showed benefit of aggressive over moderate intensity/dosage therapy (Nissen, 2005, Nissen et al., 2006, Nissen et al., 2004). The ...
Hinder the synthesis of cholesterol: can effectively inhibit the production of cholesterol in human hepatocyte HepG2, IC50 value of 5.8nmol/L, its action intensity is 29 times that of simvastatin, 57 times that of atorvastatin. However, the inhibitory effect of Pivastatin calcium on various ...
Conclusions Evolocumab safely reduced cardiovascular events in patients with stable atherosclerotic cardiovascular disease to a similar degree whether the baseline LDL-C level was less than or at least 70 mg/dL and regardless of whether the background statin dosage was maximal or submaximal intensity. ...
Effect of Alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with Acute myocardial infarction: the PACMAN-AMI Randomized Clinical Trial. JAMA. 2022;327:1771–81. https://doi.org/10.1001/jama.2022.5218. Article CAS PubMed PubMed Central Google Scholar Wu C,...